Abstract -Rosiglitazone maleate (RGM) is widely used for improving insulin resistance. RGM is a moderate inhibitor of cytochrome P450 2C8 (CYP2C8) and is also mainly metabolized by CYP2C8. The aim of this study was to determine whether the effect of RGM on CYP2C8 is altered by co-treatment with other drugs, and whether amlodipine camsylate (AC) changes the pharmacokinetics (PK) of RGM. Of the 11 drugs that are likely to be co-administered with RGM in diabetic patients, seven drugs lowered the IC 50 value of RGM on CYP2C8 by more than 80%. In vitro CYP2C8 inhibitory assays of RGM in combination with drugs of interest showed that the IC50 of RGM was decreased by 98.9% by AC. In a pharmacokinetic study, Sprague-Dawley (SD) rats were orally administered 1 mg/kg of RGM following by single or 10-consecutive daily administrations of 1.5 mg/kg/day of AC. No significant changes in the pharmacokinetic parameters of RGM were observed after a single administration of AC, but the AUC and Cmax values of RGM were significantly reduced by 36% and 31%, respectively, by multiple administrations of AC. In conclusion, RGM was found to be affected by AC by in vitro CYP2C8 inhibition testing, and multiple dosing of AC appreciably changed the pharmacokinetics of RGM. These findings suggest that a drug interaction exists between AC and RGM.
INTRODUCTION
Rosiglitazone, a second generation oral hypoglycemic thiazolidinedione, is used to treat non-insulin dependent diabetes mellitus (type 2 diabetes mellitus) (Connor et al., 1997) . Rosiglitazone is rapidly absorbed after oral administration and exhibits high bioavailability of 99%. It is mainly metabolized via N-methylation and para-hydroxylation by CYP2C8 through phase I metabolism, and to a lesser extent by CYP2C9 (Baldwin et al., 1999) . Recently, the contributions made by CYP2C8 to the metabolisms of cerivastatin, paclitaxel, repaglinide, and verapamil have been studied Tracy et al., 1999; Mück, 2000; Niemi et al., 2003a) . The pharmacokinetics of rosiglitazone is known to be altered when it is co-administered with other drugs which were involved with the induction or inhibition of CYP2C8, such as, gemfibrozil, trimethoprim and rifampin (Tracy et al., 1999; Park et al., 2004; Hruska et al., 2005) . Gemfibrozil, which has an inhibitory effect on CYP2C8, was found to increase the AUC of rosiglitazone (maximally 2.8-fold) and to prolong its elimination half-life (maximally 7.6 h) (Niemi et al., 2003b) . Moreover, rifampin, which induces CYP2C8, decreased the AUC of rosiglitazone by 65% and its elimination half-life by 62% in healthy subjects (Park et al., 2004) . Therefore, rosiglitazone has the possibility to interact with other commonly used agents. Furthermore, the IC50 values of various drugs (including rosiglitazone) for CYP2C8 were examined in vitro (Walsky et al., 2005) , and of these, 11 drugs with an IC50 of 10 μM or more and potential combination with rosiglitazone were found. Because rosiglitazone has an IC 50 value of 10 μM or more (Walsky et al., 2005) , it was supposed that drug interactions could occur between rosiglitazone and the other 11 drugs, and that these drugs when co-treated could changes its inhibitory effects on CYP2C8, because all are inhibitors of CYP2C8.
Amlodipine is a calcium channel blocker for high blood pressure and chest pain (angina). The oxidation of amlodipine is catalysed by cytochrome P450 3A4 (CYP3A4) (Beresford et al., 1988; Guengerich et al., 1991) . Hypertension is closely associated with diabetes mellitus, and amlodipine has been commonly prescribed with rosiglitazone. Moreover, it has also been reported that amlodipine is an inhibitor of CYP2C8 (Walsky et al., 2005) . Accordingly, the potential exists for a drug interaction between rosiglitazone and amlodipine.
The purpose of the present study was to evaluate the change of the inhibitory effects of 11 drugs, including amlodipine, on CYP2C8 when co-treated with rosiglitazone. Furthermore, we examined changes in the pharmacokinetics of rosiglitazone caused by amlodipine in rats.
MATERIALS AND METHODS

Materials
Rosiglitazone 
CYP2C8 inhibition test
RGM and other drugs were prepared in 1 mM stock solutions dissolved in methanol and diluted with water to 4 times for final concentration before use. The concentration of methanol in the final solution of the drugs used for incubation was 1% (v/v) or less (Busby et al. 1999) . In this test, the CYP450 reaction (n=3) was initiated by incubating RGM alone or RGM in combination with the drug of interest with rhCYP2C8 (1.0 pmol), 50 mM potassium phosphate buffer (pH 7.4), 150 μM luciferin-methyl ester, and the NADPH regeneration system, according to the Technical Bulletin of the P450-Glo TM CYP2C8 Assay. A luciferin-methyl ester is converted by CYP2C8 to a luciferin product as a luminogenic substrate of the enzyme. IC50 values were initially calculated for drugs alone and then RGM was co-treated with drugs at concentration corresponding to the IC 50 values of the drugs. The final concentrations of RGM alone and the 11 each drug alone were 0.1, 1, 5, 10, 25 and 100 μM.
Pharmacokinetic study
Male Sprague-Dawley (SD) rats were handled in accredited KFDA animal facilities in accordance with the requirements of the Association for the Assessment and Accreditation of Laboratory of Animal Care (AAALAC) (Accredited Unit, KFDA, unit no. 000996). Male SD rats (230 to 270 g) were anesthetized by intramascular injection of ketamine hydrochloride and xylazine hydrochloride and then were operated with to insert cannula into left carotid artery (Kim et al., 2006) . Water was provided, but food was withheld during the 12 h post-surgical recovery period before dosing. RGM was administered to rats at 1 mg/kg p.o. (0.75 mg as rosiglitazone) in saline following AC at 1.5 mg/kg p.o. (0.93 mg as amlodipine) in saline. AC was administered as a single dose or once daily for 10 days. On single dosing day or day 10, AC was pre-treated orally 30 min prior to RGM (Muzeeb et al., 2006) . Aminals had free access to food and water from 4 h post-dosing. Heparinized blood samples were collected from the indwelling animal model (Kim et al., 2006) . Two hundred μl of blood samples were collected at 5 min, 15 min, 45 min, 1 h, 2 h, 6 h, 9 h, 12 h, and 24 h after dosing, and plasma was harvested by centrifugation (Micro12, Han-Il Science Industrial Co., Incheon, Korea) at 10,000 rpm for 10 min. Supernatants were separated off and stored at −70°C until required for high performance liquid chromatography (HPLC) analysis.
Sample analysis
To determine RGM levels in plasma, the HPLC mobile phase consisted of 40% KH2PO4 buffer adjusted to pH 6.5 with a triethylamine, 50% acetonitrile, and 10% methanol mixture (v/v/v) (Mamidi et al., 2003) . Plasma samples were prepared by adding acetonitrile (1:2 v/v) and centrifuged at 13,000 rpm for 20 min (Kim et al., 2006) . Fifty μl aliquots of supernatants were injected into the column at a flow rate of 0.5 ml/min. The calibration curve was prepared with blank plasma to achieve final concentrations of 0.005-1 μg/ml (R 2 =0.9999). Mobile phase fluorescence was monitored using a HPLC system (Waters, Milford, MA, USA) with the excitation wavelength 247 nm, and the emission 367 nm.
Statistics
Data obtained from the CYP2C8 inhibition test are expressed as means ± standard deviations (SD) and those 
RESULTS
In vitro rhCYP2C8 inhibitory assay of RGM co-treated with the 11 drugs
The inhibitory effects of 12 drugs alone (including RGM) on rhCYP2C8 activity, were initially estimated ( Table I) . The IC50 value of RGM was 8.3 ± 0.54 μM. The other drugs from a wide variety of had IC 50 values of ＞10 μM, and their IC50 values compared with previously published data (Walsky et al., 2005) .
The IC 50 values of the other 11 drugs were 10 μM or more, which raised the possibility of interactions with RGM The time points represent 5 min, 15 min, 45 min, 1 h, 2 h, 6 h, 9 h, 12 h and 24 h after administering RGM. All data points are means ± SEs (n=5-7). and changes in the inhibitory effect of RGM on CYP2C8. When RGM was co-treated with drugs at concentrations corresponding to their IC50 values, the IC50 value of the RGM decreased to 10 μM or less (Table I) . Of these 11 drugs, seven (AC, losartan potassium, nefazodone, sertraline hydrochloride, midazolam, rabeprazole sodium and methylprednisolone) lowered the IC 50 of RGM by more than 80% (Fig. 1) . In particular, among these the IC50 (0.093 ± 0.00 μM) of RGM plus AC was about 98.9% lower than that of RGM alone (8.3 ± 0.54 μM).
Influence of single or multiple dosing with AC on the PK profile of RGM
To investigate in vivo RGM pharmacokinetic changes caused by AC, RGM was administered alone or with AC in SD rats using a cannulated indwelling model and was analyzed using HPLC. Fig. 2 shows representative chromatograms obtained from blank plasma or plasma samples. The chromatogram of blank plasma did not interfere RGM peaks and the retention times of RGM was 11.6 min.
It was found that the plasma level of RGM tended to reduce when AC was co-administered singly or daily in rats (Fig. 3) . Table II shows the pharmacokinetic parameters of RGM. The half-life (t1/2) of RGM after a single co-administration of AC was 5.9 ± 1.0 h, 1.3 times longer than RGM alone. For multiple co-administration, the t1/2 of RGM was 7.2 ± 0.9 h, 1.6 times longer than that of RGM alone (4.5 ± 0.8 h). However, these t 1/2 differences were not statistically significant. Single co-administration of RGM and AC reduced the Tmax of RGM by 25% versus RGM alone (0.6 ± 0.2 h vs. 0.8 ± 0.1 h). Multiple co-administration of AC reduced Tmax to 0.5 ± 0.1 h, which implies enhanced absorption of RGM by multiple AC treatment. The maximum RGM concentration (C max ) after a single co-administration of AC was 2.1 ± 0.3 μg/ml, which was similar to that of RGM alone (2.3 ± 0.2 μg/ml). Whereas, multiple AC co-administration significantly reduced the C max (1.6 ± 1.0 μg/ml) of RGM versus that of RGM alone (p＜0.05, t-test). The area under the curve (AUC, from zero to infinity) of RGM in after a single co-administration of AC was reduced by 21% versus RGM alone (10.6 ± 1.4 μg.h/ml vs. 13.3 ±1.7 μg.h/ml, and the AUC of RGM after multiple AC treatment was significantly decreased to 8.6 ± 1.2 μg/ml (p＜0.05, t-test).
DISCUSSION
The IC50 of RGM co-treated with AC was about 98.9% lower than that of RGM alone. These findings indicate that RGM, which is metabolized mainly by CYP2C8, inhibits the enzyme more potently in the presence of AC. AC is a substrate of CYP3A4 and also an inhibitor of CYP2C8 (Katoh et al., 2000a; Katoh et al., 2000b; Walsky et al., 2005) . There have been several reports that CYP3A4 plays a role in the metabolism of CYP2C8 substrates (e.g., cervistatin and paclitaxel) (Sonnichsen et al., 1995; Mück, 1998) . What is more, it has been reported that ketoconazole, a potent inhibitor of CYP3A4, inhibits the CYP2C8-catalysed metabolisms of torsemide and paclitaxel (Ong et al., 2000; Bun et al., 2003) . These results suggest agents that act as CYP3A4 substrates have the capacity to interact with CYP2C8. In addition, nifedipine, another Ca 2＋ channel blocker, has been shown to inhibit the conversion of paclitaxel to 6α-hydroxy paclitaxel Rahman et al., 1994) . We inferred that rosiglitazone combination therapy is likely to be altered by AC. Therefore we assumed that the pharmacokinetic parameters of RGM are likely to be altered by AC co-administration due to an altered metabolism.
CYP2C8 plays in a major role in the metabolism of RGM in the human liver. However, there is no precise equivalent to CYP2C8 in rat liver. Rat CYP2C6 mainly metabolizes RGM instead of human CYP2C8 (Beconi et al., 2003) . We expected that the PK parameters of AUC and Cmax would be higher in rat based on our in vitro data concerning the altered metabolism of RGM by AC, although limited metabolic information is available on AC caused by CYP2C6. However, our PK data showed contrary results in terms of reductions in the AUC and Cmax values of RGM by AC, which could be due to factors associated with changes in change of PK behavior, besides an altered CYP2C8 metabolism of RGM by AC, such as high bioavailability of RGM, distribution of RGM including binding to plasma protein, erythrocyte or tissue, etc.
CONCLUSIONS
These contrary results of lowered AUC and Cmax values of RGM by AC in vivo study suggest that there might be a drug interaction of RGM by AC not via metabolism in rat. To elucidate the mechanism involved, further studies should be performed such as clinical PK study, pharmacogenomics, etc.
